GRI Bio Set to Engage Investors in Virtual Event
LA JOLLA, CA – GRI Bio, Inc. (NASDAQ: GRI), a pioneering biotechnology firm, is gearing up for a significant event in the investment community. On an upcoming Wednesday, GRI Bio will participate in the Virtual Investor Closing Bell Series. This online presentation is scheduled to take place at 4:00 PM ET, providing a platform for the company to share its vision and advancements.
Event Highlights
During this engaging event, the CEO of GRI Bio, Dr. Marc Hertz, will lead a corporate overview that outlines the company’s goals and progress in developing groundbreaking therapies aimed at treating inflammatory, fibrotic, and autoimmune conditions. This session will not only feature a detailed presentation but will also include an interactive discussion, where investors and participants can submit their questions live.
Innovative Pipeline of Therapies
GRI Bio is dedicated to revolutionizing the treatment landscape for challenging diseases. Their innovative approach focuses on utilizing Natural Killer T (NKT) cell modulators to manage inflammatory and fibrotic responses effectively. By targeting NKT cells, which play a vital role in the body's immune response, GRI aims to halt disease progression and promote recovery to a state of immune balance.
Key Developments and Programs
One of the standout programs from GRI Bio is GRI-0621, an inhibitor designed specifically to regulate iNKT cell activity. This therapy is primarily being developed as an oral treatment for idiopathic pulmonary fibrosis, a disease that currently lacks effective treatment options, highlighting significant potential for GRI Bio to impact patient care positively. In addition to GRI-0621, the company is advancing a roster of diverse NKT agonists aimed at addressing systemic lupus erythematosus, further showcasing its commitment to groundbreaking treatments.
Accessing the Live Webcast
Those interested in the event can find a live video webcast on the company's website. Following the live presentation, a recording will be made available for viewers who are unable to attend in real-time. This inclusive approach ensures that more investors can engage with GRI Bio’s vision and leadership even after the live event concludes.
Staying Connected
GRI Bio's dedication to transparency and continuous communication with investors remains a cornerstone of its mission. Through events like the Virtual Investor Closing Bell Series, GRI strengthens its connection with stakeholders, keeping them informed on its innovative therapies and future aspirations.
About GRI Bio, Inc.
GRI Bio stands at the forefront of biopharmaceutical innovation, particularly in the realm of autoimmune and fibrotic diseases. The company's strategies are not just about developing new therapies but about redefining how treating these complex conditions can be approached. With an extensive library of over 500 proprietary compounds, GRI Bio boasts a robust pipeline of potential therapies that promise to address significant unmet medical needs.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
Email: GRI@jtcir.com
Frequently Asked Questions
What is the purpose of the Virtual Investor Closing Bell Series?
The series is designed to provide companies with a platform to present their corporate strategies and innovations directly to investors.
How can investors participate in the live event?
Investors can join the live webcast through the company's website on the specified date and time.
What therapeutic areas does GRI Bio focus on?
GRI Bio focuses on developing treatments for inflammatory, fibrotic, and autoimmune diseases using NKT cell modulating therapies.
What is GRI-0621?
GRI-0621 is GRI Bio's lead program aimed at inhibiting the activity of iNKT cells, intended as a treatment for idiopathic pulmonary fibrosis.
Who can I contact for more information about GRI Bio?
For further inquiries, investors can reach out to Jenene Thomas at JTC Team, LLC via email at GRI@jtcir.com or by phone at (908) 824-0775.
